Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Pharnext    ALPHA   FR0011191287

PHARNEXT (ALPHA)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
8.68(c) 8.3(c) 8.5(c) 8.7(c) 9.16 Last
21 470 18 156 8 239 7 558 12 194 Volume
-3.56% -4.38% +2.41% +2.35% +5.29% Change
More quotes
Financials (EUR)
Sales 2018 -
EBIT 2018 -18,7 M
Net income 2018 -18,7 M
Debt 2018 20,6 M
Yield 2018 -
Sales 2019 -
EBIT 2019 -20,9 M
Net income 2019 -20,8 M
Debt 2019 41,4 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 0
Capitalization 105 M
More Financials
Company
Pharnext SA develops and manufactures drugs for neurological diseases.Its products include R&D Pipeline, PXT3003, and PXT864 are used for the treatment of Charcot-Marie-Tooth disease, diabetic, and toxic peripheral neuropathies, as well as severe neurodegenerative diseases in general and peripheral... 
More about the company
Latest news on PHARNEXT
09/17PHARNEXT : David Stout joins Pharnext’s Board of Directors
PU
09/17PHARNEXT : David Stout joins Pharnext's Board of Directors
EQ
08/23PHARNEXT : Patent Issued for Compositions For Treating Amyotrophic Lateral Scler..
AQ
07/30PHARNEXT : to host a key opinion leader symposium focused on CMT1A
PU
07/20PHARNEXT : European Medicines Agency Agrees with Pharnext's Pediatric Investigat..
AQ
07/18PHARNEXT : announces issuance of composition of matter patents covering PLEODRUG..
PU
07/18PHARNEXT : Announces Issuance of New Composition of Matter Patents Covering Firs..
EQ
07/11PHARNEXT : European Medicines Agency Agrees with Pharnexts Pediatric Investigati..
AQ
07/10PXT3003 : EMA agrees with Pharnext’s pediatric investigation plan
PU
07/10PHARNEXT : European Medicines Agency Agrees with Pharnext’s Pediatric Inve..
BU
More news
Sector news : Bio Therapeutic Drugs
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/19lunchtime: a lot of action everywhere! Pharnext $ALPHA -5% argenx $ARGX -9% $.. 
09/18Biotech Time : GeNeuro, Argen-X, Pharnext, Pixium  
09/17David Stout joins Pharnext's Board of Directors
1
09/15$A2AM02 SAS 1 director sold: A director at Pharnext sold 9,200 shares at 8.9.. 
08/29??bios today:?almost everywhere, TO-low for this summer ???Oncodesign $ALONC.. 
More tweets
Qtime:8
Chart PHARNEXT
Duration : Period :
Pharnext Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARNEXT
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 15,4 €
Spread / Average Target 77%
EPS Revisions
Managers
NameTitle
Daniel Cohen Chief Executive Officer & Director
Michel de Rosen Chairman
Amit Kohli Chief Operating Officer
René Goedkoop Chief Medical Officer
Philippe Pouletty Director
Sector and Competitors
1st jan.Capitalization (M$)
PHARNEXT8.75%120
GILEAD SCIENCES5.40%97 887
VERTEX PHARMACEUTICALS20.17%46 021
REGENERON PHARMACEUTICALS3.81%41 426
NEUROCRINE BIOSCIENCES, INC.54.17%10 822
GENMAB2.04%10 170